ABSTRACT
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very specific nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations. Here is the second version of these recommendations updated according to the evolution of knowledge on COVID19.
Subject(s)
COVID-19/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adolescent , Adrenal Cortex Hormones/therapeutic use , Alanine/analogs & derivatives , Alanine/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/diagnosis , COVID-19 Nucleic Acid Testing , COVID-19 Vaccines/therapeutic use , Cancer Care Facilities , Child , Consolidation Chemotherapy , Drug Interactions , France/epidemiology , Humans , Induction Chemotherapy/methods , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Maintenance Chemotherapy/methods , Recurrence , Risk Assessment , Societies, Medical , COVID-19 Drug TreatmentABSTRACT
Data regarding coronavirus disease 2019 (COVID-19) description are still limited in pediatric oncology. The French society of pediatric oncology (SFCE) initiated a study to better describe COVID-19 in patients followed in French pediatric oncology and hematology wards. All patients diagnosed with COVID-19 and followed in a SFCE center were enrolled. Data from medical records were analyzed for all patients enrolled up to the end of May 2020. Data were available for 37 patients. Thirty-one were children under 18 years of age. Nineteen patients were female. Seventeen patients had a solid tumor, 16 had a hematological malignancy and four recently underwent hematopoietic stem cell transplantation (HSCT) for non-oncological conditions. Twenty-eight patients presented symptoms, most often with fever, cough, rhinorrhea and asthenia. Ground-glass opacities were the most frequent radiological finding with abnormalities mostly bilateral and peripherally distributed. Twenty-four patients received chemotherapy a month prior to COVID-19 diagnosis. Most patients did not require hospitalization. Three patients required oxygen at the time of diagnosis. In total, five patients were admitted in an intensive care unit because of COVID-19 and one died from the disease. Children and young adults treated for a cancer and/or with a HSCT may be at risk for severe COVID-19 and should be closely monitored.
Subject(s)
COVID-19 , Delivery of Health Care , Neoplasms , SARS-CoV-2 , Adolescent , COVID-19/epidemiology , COVID-19/therapy , Child , Child, Preschool , Female , France/epidemiology , Humans , Infant , Male , Medical Oncology , Neoplasms/epidemiology , Neoplasms/therapy , Pediatrics , Practice Guidelines as Topic , Societies, MedicalABSTRACT
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19.